TY - JOUR
T1 - Artificial Intelligence for Glaucoma
T2 - Creating and Implementing Artificial Intelligence for Disease Detection and Progression
AU - Collaborative Community for Ophthalmic Imaging Executive Committee and Glaucoma Workgroup
AU - Al-Aswad, Lama A.
AU - Ramachandran, Rithambara
AU - Schuman, Joel S.
AU - Medeiros, Felipe
AU - Eydelman, Malvina B.
AU - Abramoff, Michael D.
AU - Antony, Bhavna J.
AU - Boland, Michael V.
AU - Chauhan, Balwantray C.
AU - Chiang, Michael
AU - Goldberg, Jeffrey L.
AU - Hammel, Naama
AU - Pasquale, Louis R.
AU - Quigley, Harry A.
AU - Susanna, Remo
AU - Vianna, Jayme
AU - Zangwill, Linda
N1 - Funding Information:
Supported by the National Institutes of Health (Bethesda, MD; R01-EY013178). An unrestricted grant from Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, NYU Langone Health, NYU Grossman School of Medicine, New York, New York. L.A.A.-A.: Consultant, Advisor – Aerie Pharmaceuticals, Inc; Equity owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant support – New World Medical Inc, Save Vision Foundation; Research support, Consultant – Topcon Medical Systems Inc; Consultant – Verily. F.A.M.: Consultant – Aeri Pharmaceuticals, Allergan, Annexon, Biogen, Carl Zeiss Meditec, Galimedix, IDx, Stealth Biotherapeutics, Reichert; Financial support – Allergan, Carl Zeiss Meditec, Google Inc, Heidelberg Engineering, Novartis, Reichert; Patent – nGoggle Inc. J.S.S.: Consultant, Advisor – Aerie Pharmaceuticals, Inc, Boehringer Ingelheim, Carl Zeiss Meditec, Ocular Therapeutix, Inc, Opticient, Perfuse, Inc, Regeneron, Inc, SLACK Incorporated; Equity owner – Aerie Pharmaceuticals, Inc, Ocugenix, Ocular Therapeutix, Inc, Opticient; Grant support – BrightFocus Foundation, National Eye Institute; Patents, royalty – Carl Zeiss Meditec, Ocugenix; Intellectual property – Massachusetts Eye and Ear Infirmary and Massachusetts Institute of Technology, New York University, Tufts University, University of Pittsburgh. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided.
Funding Information:
L.A.A.-A.: Consultant, Advisor – Aerie Pharmaceuticals, Inc; Equity owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant support – New World Medical Inc, Save Vision Foundation; Research support, Consultant – Topcon Medical Systems Inc; Consultant – Verily.
Funding Information:
Supported by the National Institutes of Health (Bethesda, MD; R01-EY013178 ). An unrestricted grant from Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, NYU Langone Health, NYU Grossman School of Medicine , New York, New York.
Publisher Copyright:
© 2022 American Academy of Ophthalmology
PY - 2022/9/1
Y1 - 2022/9/1
N2 - On September 3, 2020, the Collaborative Community on Ophthalmic Imaging conducted its first 2-day virtual workshop on the role of artificial intelligence (AI) and related machine learning techniques in the diagnosis and treatment of various ophthalmic conditions. In a session entitled “Artificial Intelligence for Glaucoma,” a panel of glaucoma specialists, researchers, industry experts, and patients convened to share current research on the application of AI to commonly used diagnostic modalities, including fundus photography,OCT imaging, standard automated perimetry, and gonioscopy. The conference participants focused on the use of AI as a tool for disease prediction, highlighted its ability to address inequalities, and presented the limitations of and challenges to its clinical application. The panelists’ discussion addressed AI and health equities from clinical, societal, and regulatory perspectives.
AB - On September 3, 2020, the Collaborative Community on Ophthalmic Imaging conducted its first 2-day virtual workshop on the role of artificial intelligence (AI) and related machine learning techniques in the diagnosis and treatment of various ophthalmic conditions. In a session entitled “Artificial Intelligence for Glaucoma,” a panel of glaucoma specialists, researchers, industry experts, and patients convened to share current research on the application of AI to commonly used diagnostic modalities, including fundus photography,OCT imaging, standard automated perimetry, and gonioscopy. The conference participants focused on the use of AI as a tool for disease prediction, highlighted its ability to address inequalities, and presented the limitations of and challenges to its clinical application. The panelists’ discussion addressed AI and health equities from clinical, societal, and regulatory perspectives.
KW - Artificial intelligence
KW - Deep learning
KW - Glaucoma
KW - Imaging
UR - http://www.scopus.com/inward/record.url?scp=85129549669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129549669&partnerID=8YFLogxK
U2 - 10.1016/j.ogla.2022.02.010
DO - 10.1016/j.ogla.2022.02.010
M3 - Article
C2 - 35218987
AN - SCOPUS:85129549669
SN - 2589-4196
JO - Ophthalmology. Glaucoma
JF - Ophthalmology. Glaucoma
ER -